3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
28
Lymphoma, Mantle-Cell
14
Lymphoma, Non-Hodgkin
8
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Leukemia, B-Cell
4
Multiple Myeloma
3
Lymphoma, B-Cell
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, Follicular
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic
2
Leukemia
2
Squamous Cell Carcinoma of Head and Neck
1
Part1: Advanced B-cell Malignancies
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Hairy Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Heart Failure
1
Glioblastoma
1
DLBCL
1
Interventions
pembrolizumab
51
Nivolumab
27
Gemcitabine
23
atezolizumab
19
Cisplatin
18
Carboplatin
18
enfortumab vedotin
15
avelumab
15
Mitomycin
14
Docetaxel
8
Ipilimumab
7
Paclitaxel
6
Injections
5
Cyclophosphamide
5
vinflunine
4
toripalimab
4
tislelizumab
4
lenvatinib
4
fludarabine
4
epacadostat
4
Pemetrexed
4
130-nm albumin-bound paclitaxel
4
sacituzumab govitecan
3
disitamab vedotin
3
Rogaratinib
3
Interleukin-2
3
ALT-803
3
vofatamab
2
valrubicin
2
rucaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Transitional Cell
×
acalabrutinib
×
Clear all
NCT02351739
2019-09-10
KEYNOTE143
Acerta Pharma BV
Phase 2
Completed
78 enrolled
10 charts